MCID: BRS049
MIFTS: 55

Breast Carcinoma in Situ

Categories: Cancer diseases, Rare diseases, Reproductive diseases, Genetic diseases

Aliases & Classifications for Breast Carcinoma in Situ

MalaCards integrated aliases for Breast Carcinoma in Situ:

Name: Breast Carcinoma in Situ 12 14
Non-Infiltrating Carcinoma of Breast 12
Carcinoma in Situ of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8791
ICD10 32 D05 D05.9
ICD9CM 34 233.0
NCIt 46 C3641
SNOMED-CT 64 154636004 189336000
UMLS 69 C0154084

Summaries for Breast Carcinoma in Situ

MalaCards based summary : Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to lobular neoplasia and comedo carcinoma. An important gene associated with Breast Carcinoma in Situ is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Tamoxifen and Anastrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Breast Carcinoma in Situ

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Related Disease Score Top Affiliating Genes
1 lobular neoplasia 32.4 BRCA1 ERBB2 ESR1
2 comedo carcinoma 31.8 ERBB2 ESR1
3 ductal carcinoma in situ 29.3 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
4 female breast cancer 28.8 BRCA2 ERBB2 ESR1 PGR TP53
5 ovarian cancer 27.5 BRCA1 BRCA2 ERBB2 ESR1 KDR MET
6 breast cancer 24.2 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
7 breast apocrine carcinoma in situ 11.2
8 hereditary site-specific ovarian cancer syndrome 10.6 BRCA1 BRCA2
9 brca1 hereditary breast and ovarian cancer syndrome 10.6 BRCA1 BRCA2
10 breast reconstruction 10.6 BRCA1 BRCA2
11 breast-ovarian cancer, familial 1 10.5 BRCA1 BRCA2
12 tuberculous salpingitis 10.5 BRCA1 BRCA2 ERBB2
13 mutagen sensitivity 10.5 BRCA1 BRCA2 TP53
14 hemifacial spasm 10.5 FLT4 VEGFA
15 hereditary breast ovarian cancer syndrome 10.4 BRCA1 BRCA2 TP53
16 glioma susceptibility 1 10.4 ERBB2 TP53
17 tetraploidy 10.4 BRCA2 TP53
18 pancreas adenocarcinoma 10.4 BRCA2 TP53 VEGFA
19 li-fraumeni syndrome 10.4 BRCA1 BRCA2 TP53
20 scirrhous adenocarcinoma 10.4 ERBB2 PGR
21 breast apocrine carcinoma 10.4 ERBB2 PGR
22 endometrium carcinoma in situ 10.4 PGR TP53
23 uterine corpus serous adenocarcinoma 10.4 BRCA1 BRCA2 ERBB2 TP53
24 fallopian tube adenocarcinoma 10.4 BRCA1 BRCA2 ERBB2 TP53
25 infiltrating angiolipoma 10.3 VEGFA VEGFC
26 lymphangiosarcoma 10.3 FLT4 VEGFA VEGFC
27 differentiated thyroid carcinoma 10.3 MET TP53 VEGFA
28 pancreatic ductal adenocarcinoma 10.3 ERBB2 TP53 VEGFA
29 connective tissue cancer 10.3 FGF2 TP53 VEGFA
30 nosophobia 10.3 BRCA1 BRCA2 PGR
31 cancerophobia 10.3 BRCA1 BRCA2 PGR
32 intracystic papillary adenoma 10.3 ERBB2 PGR
33 papillary serous adenocarcinoma 10.3 BRCA1 PGR TP53
34 clear cell renal cell carcinoma 10.3 KDR TP53 VEGFA
35 dysgerminoma of ovary 10.3 BRCA1 BRCA2 PGR
36 uterine body mixed cancer 10.2 ERBB2 PGR TP53
37 microglandular adenosis 10.2 ERBB2 PGR TP53
38 progesterone-receptor negative breast cancer 10.2 ERBB2 PGR
39 angiokeratoma circumscriptum 10.2 FLT1 KDR VEGFA
40 critical limb ischemia 10.2 IL6 VEGFA
41 uterine carcinosarcoma 10.2 ERBB2 PGR TP53
42 epithelioid hemangioendothelioma 10.2 FLT1 KDR VEGFA
43 acute hemorrhagic leukoencephalitis 10.2 FLT1 KDR VEGFA
44 breast secretory carcinoma 10.2 ERBB2 FGFR1 PGR
45 radiation proctitis 10.2 FGF2 KDR VEGFA
46 glomeruloid hemangioma 10.2 FLT1 VEGFA
47 serous cystadenocarcinoma 10.2 PGR TP53 VEGFA
48 microvascular complications of diabetes 1 10.2 FGF2 FLT1 VEGFA
49 cystadenocarcinoma 10.2 PGR TP53 VEGFA
50 placental insufficiency 10.2 FLT1 KDR VEGFA

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to Breast Carcinoma in Situ

Symptoms & Phenotypes for Breast Carcinoma in Situ

GenomeRNAi Phenotypes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.55 FGFR1 KDR ESR1
2 Decreased viability GR00221-A-2 9.55 FGFR1 FLT1 FLT4 KDR BRCA1 ESR1
3 Decreased viability GR00221-A-3 9.55 KDR BRCA1
4 Decreased viability GR00221-A-4 9.55 KDR ESR1
5 Decreased viability GR00301-A 9.55 BRCA1
6 Decreased viability GR00342-S-1 9.55 FLT4
7 Decreased viability GR00342-S-2 9.55 FLT4
8 Decreased viability GR00342-S-3 9.55 FLT4
9 Decreased substrate adherent cell growth GR00193-A-1 9.35 MET
10 Decreased substrate adherent cell growth GR00193-A-3 9.35 MET
11 Decreased substrate adherent cell growth GR00193-A-4 9.35 FGFR1 KDR MET

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

43 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.51 ERBB2 BRCA1 FLT4 KDR IL6 FLT1
2 cellular MP:0005384 10.48 BRCA1 ERBB2 BRCA2 FLT1 IL6 FGFR1
3 behavior/neurological MP:0005386 10.46 BRCA1 ERBB2 BRCA2 IL6 FLT1 FGFR1
4 homeostasis/metabolism MP:0005376 10.46 BRCA1 ERBB2 BRCA2 FLT4 FLT1 IL6
5 embryo MP:0005380 10.44 ERBB2 BRCA2 BRCA1 FLT4 KDR FLT1
6 growth/size/body region MP:0005378 10.42 BRCA2 BRCA1 ERBB2 FLT1 IL6 FLT4
7 mortality/aging MP:0010768 10.42 ERBB2 BRCA2 BRCA1 FLT4 KDR FLT1
8 immune system MP:0005387 10.39 BRCA1 BRCA2 FLT1 IL6 FLT4 FGFR1
9 digestive/alimentary MP:0005381 10.38 ERBB2 BRCA2 BRCA1 FLT4 IL6 ESR1
10 endocrine/exocrine gland MP:0005379 10.36 BRCA1 ERBB2 BRCA2 IL6 ESR1 FGFR1
11 hematopoietic system MP:0005397 10.35 BRCA2 BRCA1 FLT1 IL6 ESR1 FGFR1
12 integument MP:0010771 10.35 ERBB2 BRCA2 BRCA1 FLT4 KDR IL6
13 muscle MP:0005369 10.32 ERBB2 BRCA1 FLT4 KDR IL6 FLT1
14 nervous system MP:0003631 10.28 BRCA1 ERBB2 BRCA2 FLT1 IL6 ESR1
15 neoplasm MP:0002006 10.2 ERBB2 BRCA2 BRCA1 IL6 FGF2 ESR1
16 limbs/digits/tail MP:0005371 10.18 BRCA1 ERBB2 BRCA2 ESR1 FGFR1 TP53
17 normal MP:0002873 10.18 ERBB2 BRCA2 BRCA1 FLT4 FLT1 FGFR1
18 liver/biliary system MP:0005370 10.11 IL6 FLT4 ESR1 TP53 MET VEGFA
19 adipose tissue MP:0005375 10.1 BRCA1 IL6 FLT4 ESR1 TP53 LIF
20 reproductive system MP:0005389 10.1 ERBB2 BRCA2 BRCA1 FLT4 IL6 FLT1
21 no phenotypic analysis MP:0003012 10.06 FLT4 ESR1 FGFR1 TP53 PGR MET
22 renal/urinary system MP:0005367 9.87 BRCA1 IL6 FGFR1 ESR1 TP53 MET
23 respiratory system MP:0005388 9.81 BRCA1 IL6 ESR1 ERBB2 TP53 MET
24 skeleton MP:0005390 9.77 BRCA1 ERBB2 BRCA2 IL6 FGFR1 FGF2
25 vision/eye MP:0005391 9.28 FLT1 IL6 FGFR1 FGF2 TP53 MET

Drugs & Therapeutics for Breast Carcinoma in Situ

Drugs for Breast Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
2
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
3
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
4
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
5
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
6
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
7 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
8 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1
13 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
14 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
16 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Chelating Agents Phase 4,Phase 3,Phase 2
19 Anticoagulants Phase 4,Phase 3,Phase 2
20 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
21 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
22
Progesterone Approved, Vet_approved Phase 3,Phase 2,Early Phase 1 57-83-0 5994
23
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
24
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
26
Norethindrone Approved Phase 3 68-22-4 6230
27
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
28
Metformin Approved Phase 3,Phase 1 657-24-9 4091 14219
29
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
30
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
31 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
32 Estradiol valerate Phase 3,Phase 2 979-32-8
33 Estradiol 17 beta-cypionate Phase 3,Phase 2
34 Estradiol 3-benzoate Phase 3,Phase 2
35 Polyestradiol phosphate Phase 3,Phase 2
36
Medroxyprogesterone Phase 3 520-85-4 10631
37 mometasone furoate Phase 3
38 Analgesics Phase 3,Phase 2,Phase 1
39 Central Nervous System Depressants Phase 3
40 Adjuvants, Anesthesia Phase 3
41 Narcotics Phase 3,Phase 2
42 Neurotransmitter Agents Phase 3
43 Contraceptive Agents Phase 3,Early Phase 1
44 Contraceptive Agents, Male Phase 3
45 Contraceptives, Oral Phase 3,Early Phase 1
46 Analgesics, Opioid Phase 3
47 Norethindrone acetate Phase 3
48 Anesthetics Phase 3,Phase 1
49 Dermatologic Agents Phase 3,Phase 2
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 223)

# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Not yet recruiting NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
4 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
5 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
6 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
7 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
8 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
9 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
10 Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
11 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
14 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
15 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
16 Oxybutynin Chloride in Managing Hot Flashes Recruiting NCT02961790 Phase 3 Oxybutynin Chloride
17 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02954874 Phase 3
18 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
19 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
20 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
21 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
22 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
23 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
24 Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation Active, not recruiting NCT00673335 Phase 3 letrozole;Placebo
25 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
26 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
27 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
28 Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer Unknown status NCT00096369 Phase 2 tamoxifen citrate
29 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
30 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
31 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2 Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
32 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
33 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
34 Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer Completed NCT02556632 Phase 2 Curcumin-based Gel
35 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
36 Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer Completed NCT00084539 Phase 2
37 Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy Completed NCT00843167 Phase 2
38 Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer Completed NCT00054301 Phase 2
39 Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease Completed NCT00031720 Phase 2 Tamoxifen
40 Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
41 Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer Completed NCT00354640 Phase 2 anastrozole;simvastatin
42 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Completed NCT00764322 Phase 2 tamoxifen citrate
43 Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer Completed NCT00244959 Phase 2 anastrozole
44 Letrozole in Preventing Breast Cancer in Postmenopausal Women Completed NCT00090857 Phase 2 Letrozole
45 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
46 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
47 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
48 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ Completed NCT00586326 Phase 2
49 Single Fraction Intraoperative Radiotherapy Recruiting NCT01688388 Phase 1, Phase 2
50 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Recruiting NCT02993159 Phase 2 Afimoxifene;Tamoxifen Citrate

Search NIH Clinical Center for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

MalaCards organs/tissues related to Breast Carcinoma in Situ:

38
Breast, Skin, Bone, Testes, Prostate, Lymph Node, Liver

Publications for Breast Carcinoma in Situ

Articles related to Breast Carcinoma in Situ:

(show all 45)
# Title Authors Year
1
Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort. ( 28286675 )
2017
2
Mammographic extent of microcalcifications and oestrogen receptor expression affect preoperative breast carcinoma in situ size estimation. ( 27639877 )
2016
3
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. ( 27926499 )
2016
4
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. ( 26062614 )
2015
5
Usefulness and limitations of E-cadherin and I^-catenin in the classification of breast carcinomas in situ with mixed pattern. ( 23837653 )
2013
6
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. ( 22595929 )
2012
7
Differences in breast carcinoma in situ between menopausal and premenopausal women. ( 21617240 )
2011
8
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? ( 19896281 )
2010
9
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. ( 21149333 )
2010
10
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. ( 20565829 )
2010
11
Prevalence of breast carcinoma in situ in the United States. ( 19706857 )
2009
12
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). ( 18317962 )
2008
13
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. ( 18665169 )
2008
14
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. ( 17063272 )
2007
15
Cigarette smoking and risk of breast carcinoma in situ. ( 17700252 )
2007
16
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. ( 17244359 )
2007
17
Oral contraceptive use and risk of breast carcinoma in situ. ( 18006914 )
2007
18
Molecular classification of breast carcinoma in situ. ( 17375183 )
2006
19
Oral contraceptive use and risk of breast carcinoma in situ (United States). ( 17006721 )
2006
20
Quality of life for women diagnosed with breast carcinoma in situ. ( 17050872 )
2006
21
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. ( 15540225 )
2005
22
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. ( 15841074 )
2005
23
Impact of reproductive factors and lactation on breast carcinoma in situ risk. ( 15054874 )
2004
24
Oral contraceptives and the risk of ductal breast carcinoma in situ. ( 14572155 )
2003
25
Proliferative lesions of the breast: carcinoma in situ. ( 15022899 )
2003
26
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. ( 12670886 )
2003
27
Lifetime recreational exercise activity and risk of breast carcinoma in situ. ( 14601085 )
2003
28
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. ( 14659121 )
2003
29
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. ( 12611452 )
2003
30
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. ( 12118344 )
2002
31
Breast carcinoma in situ: risk factors and screening patterns. ( 11734598 )
2001
32
p53 mutations and expression in breast carcinoma in situ. ( 10623666 )
2000
33
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. ( 9622698 )
1998
34
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. ( 9071907 )
1997
35
Biological heterogeneity of breast carcinoma in situ. ( 8651598 )
1996
36
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. ( 8692711 )
1996
37
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. ( 7654052 )
1995
38
Breast carcinoma in situ. ( 20169700 )
1992
39
Breast carcinoma-in-situ: an emerging problem in Singapore. ( 1329232 )
1992
40
Receptors for estrogen and progesterone in breast carcinoma in situ. ( 1295456 )
1992
41
Ten-year follow-up of breast carcinoma in situ in Connecticut. ( 1365682 )
1992
42
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. ( 1677296 )
1991
43
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. ( 1657650 )
1991
44
Breast carcinoma in situ. ( 2535929 )
1989
45
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. ( 2990246 )
1985

Variations for Breast Carcinoma in Situ

Expression for Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for Breast Carcinoma in Situ

Pathways related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 ERBB2 ESR1 FGF2 FGFR1 FLT1 FLT4
2
Show member pathways
13.91 ERBB2 FGF2 FGFR1 FLT1 FLT4 IL6
3
Show member pathways
13.84 BRCA1 ERBB2 ESR1 FGF2 FGFR1 FLT1
4
Show member pathways
13.73 ERBB2 FGFR1 FLT1 FLT4 IL6 KDR
5
Show member pathways
13.73 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
6
Show member pathways
13.59 ERBB2 FGF2 FGFR1 FLT1 FLT4 IL6
7
Show member pathways
13.59 BRCA1 ERBB2 FGF2 FGFR1 FLT1 FLT4
8
Show member pathways
13.48 ERBB2 FGF2 FGFR1 FLT1 FLT4 IL6
9
Show member pathways
13.4 ERBB2 FGF2 FGFR1 IL6 LIF MET
10
Show member pathways
13.4 ERBB2 FGF2 FGFR1 FLT1 FLT4 IL6
11
Show member pathways
13.39 ERBB2 FGF2 FGFR1 FLT1 FLT4 IL6
12
Show member pathways
13.35 ERBB2 ESR1 FGF2 FGFR1 FLT1 FLT4
13
Show member pathways
13.16 FGF2 FGFR1 FLT1 FLT4 IL6 KDR
14
Show member pathways
13.14 FGF2 FGFR1 FLT1 FLT4 IL6 KDR
15
Show member pathways
13.12 BRCA1 BRCA2 ERBB2 FGF2 FGFR1 IL6
16
Show member pathways
13.03 ERBB2 FGFR1 FLT1 FLT4 KDR MET
17
Show member pathways
12.98 ERBB2 FLT1 FLT4 KDR MET VEGFA
18
Show member pathways
12.83 FGF2 FGFR1 FLT1 FLT4 KDR MET
19 12.81 FGF2 FGFR1 FLT1 FLT4 KDR MET
20
Show member pathways
12.79 FGF2 FGFR1 FLT1 FLT4 IL6 KDR
21
Show member pathways
12.76 ERBB2 FGF2 FGFR1 MET TP53
22
Show member pathways
12.72 BRCA1 FGF2 FGFR1 FLT1 FLT4 IL6
23
Show member pathways
12.66 FLT1 FLT4 KDR VEGFA VEGFC
24
Show member pathways
12.62 ERBB2 ESR1 TP53 VEGFA VEGFC
25
Show member pathways
12.62 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
26
Show member pathways
12.61 ERBB2 FGFR1 FLT1 FLT4 KDR MET
27 12.57 BRCA1 ERBB2 MET TP53 VEGFA
28
Show member pathways
12.56 ERBB2 FGFR1 FLT1 FLT4 KDR MET
29
Show member pathways
12.5 ERBB2 MET TP53 VEGFA
30
Show member pathways
12.46 FGF2 FGFR1 FLT1 FLT4 KDR MET
31
Show member pathways
12.45 FLT1 FLT4 KDR VEGFA VEGFC
32
Show member pathways
12.43 BRCA1 ESR1 KDR VEGFA
33
Show member pathways
12.36 FGF2 FGFR1 FLT1 KDR VEGFA VEGFC
34
Show member pathways
12.34 ERBB2 FGFR1 FLT1 FLT4 KDR MET
35 12.29 FLT1 IL6 MET TP53
36 12.28 ERBB2 ESR1 FGF2 FGFR1 KDR MET
37 12.25 BRCA1 BRCA2 ESR1 TP53 VEGFA
38
Show member pathways
12.2 BRCA2 ERBB2 TP53 VEGFA
39 12.12 FGF2 IL6 KDR KRT19 LIF MET
40 12.1 FLT1 KDR TP53 VEGFA
41 12.1 FGF2 IL6 LIF TP53 VEGFA
42 12.09 BRCA2 ERBB2 ESR1 FGF2 FGFR1 FLT4
43
Show member pathways
12 FLT1 FLT4 KDR VEGFA VEGFC
44 11.99 ERBB2 FLT1 IL6 VEGFA
45 11.97 FGF2 FGFR1 FLT1 FLT4 KDR VEGFC
46 11.92 IL6 VEGFA VEGFC
47
Show member pathways
11.9 FGFR1 FLT1 FLT4 KDR
48
Show member pathways
11.89 ERBB2 ESR1 VEGFA
49 11.87 FLT1 IL6 VEGFA
50
Show member pathways
11.84 BRCA1 BRCA2 TP53

GO Terms for Breast Carcinoma in Situ

Cellular components related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 FGF2 FGFR1 FLT1 FLT4 IL6 KDR
2 receptor complex GO:0043235 9.26 ERBB2 FGFR1 FLT1 FLT4

Biological processes related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 9.97 ERBB2 FGFR1 FLT1 FLT4 KDR
2 positive regulation of protein phosphorylation GO:0001934 9.95 ERBB2 FLT4 KDR VEGFA
3 positive regulation of protein kinase B signaling GO:0051897 9.95 ERBB2 FGF2 FGFR1 MET
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.95 ERBB2 FLT1 FLT4 KDR MET
5 phosphatidylinositol phosphorylation GO:0046854 9.91 ERBB2 FGF2 FGFR1 MET
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.91 IL6 LIF TP53 VEGFA VEGFC
7 lung development GO:0030324 9.88 FGFR1 LIF VEGFA
8 wound healing GO:0042060 9.88 ERBB2 FGF2 TP53
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.87 IL6 LIF VEGFA
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 FGFR1 FLT1 KDR
11 angiogenesis GO:0001525 9.87 FGF2 FGFR1 FLT1 FLT4 KDR VEGFA
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IL6 LIF VEGFA
13 response to estrogen GO:0043627 9.85 BRCA1 ESR1 KRT19
14 positive regulation of epithelial cell proliferation GO:0050679 9.85 ERBB2 VEGFA VEGFC
15 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.85 FLT1 FLT4 KDR VEGFA VEGFC
16 positive regulation of angiogenesis GO:0045766 9.85 BRCA1 FGF2 FLT1 KDR VEGFA VEGFC
17 positive chemotaxis GO:0050918 9.84 FGF2 MET VEGFA VEGFC
18 positive regulation of endothelial cell migration GO:0010595 9.83 FLT4 KDR VEGFA
19 positive regulation of cell division GO:0051781 9.83 FGF2 VEGFA VEGFC
20 positive regulation of blood vessel endothelial cell migration GO:0043536 9.83 FGF2 KDR VEGFA VEGFC
21 positive regulation of endothelial cell proliferation GO:0001938 9.83 FGF2 FLT4 KDR VEGFA VEGFC
22 regulation of angiogenesis GO:0045765 9.8 ERBB2 FGF2 IL6
23 lung alveolus development GO:0048286 9.8 FLT4 LIF PGR
24 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.8 FLT1 FLT4 KDR VEGFA
25 positive regulation of MAP kinase activity GO:0043406 9.8 ERBB2 FGF2 FGFR1 FLT1 VEGFA
26 blood vessel morphogenesis GO:0048514 9.79 FGFR1 FLT1 FLT4
27 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.77 BRCA1 BRCA2 TP53
28 cell migration involved in sprouting angiogenesis GO:0002042 9.76 FGF2 KDR VEGFA
29 vascular endothelial growth factor signaling pathway GO:0038084 9.74 FLT1 FLT4 KDR
30 positive regulation of MAPK cascade GO:0043410 9.73 FGFR1 FLT1 FLT4 IL6 KDR LIF
31 induction of positive chemotaxis GO:0050930 9.71 VEGFA VEGFC
32 positive regulation of positive chemotaxis GO:0050927 9.7 KDR VEGFA
33 positive regulation of protein kinase C signaling GO:0090037 9.68 FLT4 VEGFA
34 positive regulation of mast cell chemotaxis GO:0060754 9.67 VEGFA VEGFC
35 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.66 KDR VEGFA
36 chordate embryonic development GO:0043009 9.65 BRCA1 BRCA2 FGFR1
37 positive regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000546 9.64 FGF2 FGFR1
38 positive regulation of cell proliferation GO:0008284 9.61 FGF2 FGFR1 FLT1 FLT4 IL6 KDR
39 positive regulation of phospholipase C activity GO:0010863 9.46 ESR1 FGF2 FGFR1 FLT1
40 peptidyl-tyrosine phosphorylation GO:0018108 9.17 ERBB2 FGF2 FGFR1 FLT1 FLT4 KDR
41 multicellular organism development GO:0007275 10.22 FGF2 FLT1 KDR LIF TP53 VEGFA
42 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 BRCA1 ESR1 FGF2 IL6 LIF MET
43 cell differentiation GO:0030154 10.18 FGF2 FLT1 KDR TP53 VEGFA VEGFC
44 phosphorylation GO:0016310 10.14 ERBB2 FGFR1 FLT1 FLT4 KDR MET
45 protein phosphorylation GO:0006468 10.12 ERBB2 FGFR1 FLT1 FLT4 KDR MET
46 positive regulation of transcription, DNA-templated GO:0045893 10.11 BRCA1 BRCA2 ESR1 FGF2 IL6 TP53
47 negative regulation of apoptotic process GO:0043066 10.09 FLT4 IL6 KDR TP53 VEGFA
48 regulation of receptor activity GO:0010469 10.08 FGF2 IL6 LIF VEGFA VEGFC
49 positive regulation of gene expression GO:0010628 10.08 BRCA1 ERBB2 IL6 LIF TP53 VEGFA
50 MAPK cascade GO:0000165 10 ERBB2 FGF2 FGFR1 MET

Molecular functions related to Breast Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.99 ERBB2 FGFR1 FLT1 FLT4 KDR MET
2 cytokine activity GO:0005125 9.85 FGF2 IL6 LIF VEGFA
3 identical protein binding GO:0042802 9.81 BRCA2 ERBB2 ESR1 FGFR1 KDR MET
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.8 ERBB2 FGF2 FGFR1 MET
5 growth factor activity GO:0008083 9.77 FGF2 IL6 LIF VEGFA VEGFC
6 protein phosphatase binding GO:0019903 9.73 ERBB2 FLT4 MET TP53
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.71 ERBB2 FGF2 FGFR1 MET
8 chemoattractant activity GO:0042056 9.65 FGF2 VEGFA VEGFC
9 growth factor binding GO:0019838 9.62 ERBB2 FLT1 FLT4 KDR
10 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.56 ERBB2 KDR
11 receptor-receptor interaction GO:0090722 9.52 FGF2 FGFR1
12 protein tyrosine kinase activity GO:0004713 9.5 ERBB2 FGF2 FGFR1 FLT1 FLT4 KDR
13 vascular endothelial growth factor-activated receptor activity GO:0005021 9.43 FLT1 FLT4 KDR
14 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.1 ERBB2 FGFR1 FLT1 FLT4 KDR MET
15 protein binding GO:0005515 10.39 BRCA1 BRCA2 ERBB2 ESR1 FGF2 FGFR1
16 kinase activity GO:0016301 10.01 ERBB2 FGFR1 FLT1 FLT4 KDR MET

Sources for Breast Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....